These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 31630993)

  • 1. Ethnic disparities among men with prostate cancer undergoing germline testing.
    Kwon DH; Borno HT; Cheng HH; Zhou AY; Small EJ
    Urol Oncol; 2020 Mar; 38(3):80.e1-80.e7. PubMed ID: 31630993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Germline Variant Spectrum Among African American Men Undergoing Prostate Cancer Germline Testing: Need for Equity in Genetic Testing.
    Giri VN; Hartman R; Pritzlaff M; Horton C; Keith SW
    JCO Precis Oncol; 2022 May; 6(1):e2200234. PubMed ID: 35666082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Germline alterations among Hispanic men with prostate cancer.
    Pan E; Shaya J; Madlensky L; Randall JM; Javier-Desloges J; Millard FE; Rose B; Parsons JK; Nielsen SM; Hatchell KE; Esplin ED; Nussbaum RL; Weise N; Murphy J; Martinez ME; McKay RR
    Prostate Cancer Prostatic Dis; 2022 Sep; 25(3):561-567. PubMed ID: 35228665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inequities in multi-gene hereditary cancer testing: lower diagnostic yield and higher VUS rate in individuals who identify as Hispanic, African or Asian and Pacific Islander as compared to European.
    Ndugga-Kabuye MK; Issaka RB
    Fam Cancer; 2019 Oct; 18(4):465-469. PubMed ID: 31531760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic Outcomes of Concurrent DNA and RNA Sequencing in Individuals Undergoing Hereditary Cancer Testing.
    Horton C; Hoang L; Zimmermann H; Young C; Grzybowski J; Durda K; Vuong H; Burks D; Cass A; LaDuca H; Richardson ME; Harrison S; Chao EC; Karam R
    JAMA Oncol; 2024 Feb; 10(2):212-219. PubMed ID: 37924330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Germline genetic variants in men with prostate cancer and one or more additional cancers.
    Pilié PG; Johnson AM; Hanson KL; Dayno ME; Kapron AL; Stoffel EM; Cooney KA
    Cancer; 2017 Oct; 123(20):3925-3932. PubMed ID: 28657667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rates and Classification of Variants of Uncertain Significance in Hereditary Disease Genetic Testing.
    Chen E; Facio FM; Aradhya KW; Rojahn S; Hatchell KE; Aguilar S; Ouyang K; Saitta S; Hanson-Kwan AK; Capurro NN; Takamine E; Jamuar SS; McKnight D; Johnson B; Aradhya S
    JAMA Netw Open; 2023 Oct; 6(10):e2339571. PubMed ID: 37878314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Racial and ethnic variation in BRCA1 and BRCA2 genetic test results among individuals referred for genetic counseling at a large urban comprehensive cancer center.
    Abdallah N; Purrington KS; Tatineni S; Assad H; Petrucelli N; Simon MS
    Cancer Causes Control; 2023 Feb; 34(2):141-149. PubMed ID: 36370215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Germline variants of uncertain significance, their frequency, and clinico-pathological features in a cohort of Sri Lankan patients with hereditary breast cancer.
    Gunawardena K; Sirisena ND; Anandagoda G; Neththikumara N; Dissanayake VHW
    BMC Res Notes; 2023 Jun; 16(1):95. PubMed ID: 37277882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene-based Confirmatory Germline Testing Following Tumor-only Sequencing of Prostate Cancer.
    Truong H; Breen K; Nandakumar S; Sjoberg DD; Kemel Y; Mehta N; Lenis AT; Reisz PA; Carruthers J; Benfante N; Joseph V; Khurram A; Gopalan A; Fine SW; Reuter VE; Vickers AJ; Birsoy O; Liu Y; Walsh M; Latham A; Mandelker D; Stadler ZK; Pietzak E; Ehdaie B; Touijer KA; Laudone VP; Slovin SF; Autio KA; Danila DC; Rathkopf DE; Eastham JA; Chen Y; Morris MJ; Offit K; Solit DB; Scher HI; Abida W; Robson ME; Carlo MI
    Eur Urol; 2023 Jan; 83(1):29-38. PubMed ID: 36115772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of germline variants in Brazilian breast cancer patients using multigene panel testing.
    Guindalini RSC; Viana DV; Kitajima JPFW; Rocha VM; López RVM; Zheng Y; Freitas É; Monteiro FPM; Valim A; Schlesinger D; Kok F; Olopade OI; Folgueira MAAK
    Sci Rep; 2022 Mar; 12(1):4190. PubMed ID: 35264596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer.
    Isaacsson Velho P; Silberstein JL; Markowski MC; Luo J; Lotan TL; Isaacs WB; Antonarakis ES
    Prostate; 2018 Apr; 78(5):401-407. PubMed ID: 29368341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating Germline Testing Panels in Southern African Males With Advanced Prostate Cancer.
    Gheybi K; Jiang J; Mutambirwa SBA; Soh PXY; Kote-Jarai Z; Jaratlerdsiri W; Eeles RA; Bornman MSR; Hayes VM
    J Natl Compr Canc Netw; 2023 Mar; 21(3):289-296.e3. PubMed ID: 36898365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer.
    Ledet EM; Burgess EF; Sokolova AO; Jaeger EB; Hatton W; Moses M; Miller P; Cotogno P; Layton J; Barata P; Lewis BE; Nakazawa M; Zhu J; Dellinger B; Elrefai S; Nafissi NN; Egan JB; Shore N; McKay RR; Bryce AH; Cheng HH; Antonarakis ES; Sartor O
    Prostate; 2021 May; 81(7):433-439. PubMed ID: 33792945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Germline pathogenic variants in unselected Korean men with prostate cancer.
    So MK; Ahn HK; Huh J; Kim KH
    Investig Clin Urol; 2022 May; 63(3):294-300. PubMed ID: 35534218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rare germline genetic variants and risk of aggressive prostate cancer.
    Nguyen-Dumont T; MacInnis RJ; Steen JA; Theys D; Tsimiklis H; Hammet F; Mahmoodi M; Pope BJ; Park DJ; Mahmood K; Severi G; Bolton D; Milne RL; Giles GG; Southey MC
    Int J Cancer; 2020 Oct; 147(8):2142-2149. PubMed ID: 32338768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preconception carrier screening yield: effect of variants of unknown significance in partners of carriers with clinically significant variants.
    Fridman H; Behar DM; Carmi S; Levy-Lahad E
    Genet Med; 2020 Mar; 22(3):646-653. PubMed ID: 31624327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Internet-Based Germline Genetic Testing for Men With Metastatic Prostate Cancer.
    Cheng HH; Sokolova AO; Gulati R; Bowen D; Knerr SA; Klemfuss N; Grivas P; Hsieh A; Lee JK; Schweizer MT; Yezefski T; Zhou A; Yu EY; Nelson PS; Montgomery B
    JCO Precis Oncol; 2023 Jan; 7():e2200104. PubMed ID: 36623239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Germline Variants in DNA Damage Repair Genes and
    Trendowski MR; Sample C; Baird T; Sadeghpour A; Moon D; Ruterbusch JJ; Beebe-Dimmer JL; Cooney KA
    JCO Precis Oncol; 2022 Nov; 6():e2200460. PubMed ID: 36446039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of Germline Variants in Patients With Localized and Metastatic Prostate Cancer Through Guideline-Based Testing.
    Abusamra SM; Solorzano MA; Quarles J; Luke M; Patel M; Vince R; Jiang R; Volin J; Jacobs MF; Kaffenberger SD; Salami SS; Palmbos P; Caram MEV; Hollenbeck BK; Palapattu GS; Merajver SD; Stoffel EM; Hafron J; Morgan TM; Reichert ZR
    Urol Pract; 2025 Jan; 12(1):63-72. PubMed ID: 39383006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.